{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:23:24Z","timestamp":1754151804560,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study was conducted to determine the prognostic relevance of neutrophil\/eosinophil ratio (NER) in cancer patients receiving immune checkpoint inhibition therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of the literature was carried out across PubMed, EMBASE, and the Cochrane Library to identify relevant studies published before May 2025. Key clinical endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, a retrospective cohort analysis involving 67 hepatocellular carcinoma (HCC) patients who received ICIs at our center was undertaken to evaluate the prognostic significance of NER with respect to OS and PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis incorporated 12 studies comprising a total of 1,716 patients. Higher baseline NER was consistently associated with poorer clinical outcomes, including shorter OS (HR = 1.82, 95% CI: 1.57\u20132.11, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and PFS (HR = 1.62, 95% CI: 1.34\u20132.97, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), as well as lower ORR (HR = 0.50, 95% CI: 0.37\u20130.68, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and DCR (OR = 0.44, 95% CI: 0.31\u20130.61, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Complementing these findings, analysis of a retrospective cohort from our institution involving HCC patients revealed that individuals with higher NER experienced significantly worse OS (<jats:italic>p<\/jats:italic> = 0.006) and PFS (<jats:italic>p<\/jats:italic> = 0.033) when compared to those with lower NER levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings underscore the prognostic significance of pretreatment NER in cancer patients receiving ICI therapy. Integrating NER into standard clinical evaluation may enhance risk stratification and contribute to the personalization of treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1633034","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:10:41Z","timestamp":1753071041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The predictive value of the neutrophil\/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.2013.13805","article-title":"The state of US health, 1990-2010: burden of diseases, injuries, and risk factors","volume":"310","author":"Murray","year":"2013","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-023-01845-4","article-title":"Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy","volume":"22","author":"Sordo-Bahamonde","year":"2023","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896752","article-title":"Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cllc.2018.04.008","article-title":"Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer","volume":"19","author":"Zer","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102099","DOI":"10.1016\/j.clgc.2024.102099","article-title":"Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced urothelial carcinoma enrolled in the MALVA study (Meet-URO 25)","volume":"22","author":"Gambale","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226x.2024.40390","article-title":"Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab\/nivolumab","volume":"63","author":"Beulque","year":"2024","journal-title":"Acta Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22224","article-title":"Prognostic impact of baseline neutrophil-to-eosinophil ratio in patients with metastatic renal cell carcinoma treated with nivolumab therapy in second or later lines","volume":"14","author":"Gil","year":"2022","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36401\/jipo-24-19","article-title":"Real-world outcomes in patients with advanced penile squamous cell carcinoma receiving immune checkpoint inhibitors: A single institution experience","volume":"8","author":"Zhuang","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13109","article-title":"Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy","volume":"36","author":"Pozorski","year":"2023","journal-title":"Pigment Cell Melanoma Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"110200","DOI":"10.1016\/j.intimp.2023.110200","article-title":"The use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in advanced esophagogastric cancer","volume":"119","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1018411","article-title":"Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume-title":"European J Cancer","author":"Schwartz","year":"2016"},{"key":"B18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1186\/s12885-024-12579-x","article-title":"Impact of baseline body composition on prognostic outcomes in urological Malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2395062","DOI":"10.1080\/07853890.2024.2395062","article-title":"Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12937-024-01037-w","article-title":"Body composition as a prognostic factor in cholangiocarcinoma: a meta-analysis","volume":"23","author":"Zhang","year":"2024","journal-title":"Nutr J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14340","article-title":"Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity","volume":"10","author":"Liang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S382771","article-title":"Association of\u00a0pretreatment neutrophil-to-eosinophil ratio with clinical outcomes in patients\u00a0with recurrent or metastatic head and neck squamous cell carcinoma treated\u00a0with nivolumab","volume":"14","author":"Suzuki","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_910_20","article-title":"Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid Malignancies","volume":"17","author":"Varayathu","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17588359251316243","DOI":"10.1177\/17588359251316243","article-title":"Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors","volume":"17","author":"Yildirim","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000181","article-title":"Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial","volume":"3","author":"Tucker","year":"2024","journal-title":"BMJ Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-021-00334-4","article-title":"Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma","volume":"9","author":"Tucker","year":"2021","journal-title":"biomark Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S333823","article-title":"The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab","volume":"13","author":"Furubayashi","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"110019","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220011","article-title":"Neutrophil phenotypes and functions in cancer: A consensus statement","volume":"219","author":"Quail","year":"2022","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1319","article-title":"IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.pt.2016.05.004","article-title":"Eosinophils in helminth infection: defenders and dupes","volume":"32","author":"Huang","year":"2016","journal-title":"Trends Parasitol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clnu.2023.11.009","article-title":"Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers","volume":"43","author":"Lilong","year":"2024","journal-title":"Clin Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000446","article-title":"Human\u00a0eosinophils exert TNF-\u03b1 and granzyme A-mediated tumoricidal activity toward colon carcinoma cells","volume":"185","author":"Legrand","year":"2010","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326083","article-title":"Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12371","article-title":"CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis","volume":"21","author":"Xing","year":"2016","journal-title":"Genes Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219929","article-title":"Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12967-023-03940-y","article-title":"Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma","volume":"21","author":"Zhang","year":"2023","journal-title":"J Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1286583","article-title":"Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Nutr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1633034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:10:41Z","timestamp":1753071041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1633034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1633034"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1633034","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"article-number":"1633034"}}